The efficacy of remimazolam tosylate versus propofol in cardiac function in patients with sepsis : a multicentered, randomized, parallel-controlled clinical trial

The efficacy of remimazolam tosylate versus propofol in cardiac function in patients with sepsis: a multicentered, randomized, parallel-controlled clinical trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054137

Enrollment

Unknown

Registered

2021-12-09

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

remimazolam tosylate Group(Experimental group):remimazolam tosylate+sufentanil

Control group:Sufentanil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. All enrolled patients meet the diagnostic criteria for sepsis version 3.0; 2. No history of heart disease; 3. 18-75 years old, no gender limit; 4. The patient or family member has signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Previous heart surgery, such as valve replacement, coronary artery bypass grafting, etc.; 2. Cardiac insufficiency on admission, EF<50%; 3. Long-term coma due to cerebrovascular accident in the past; 4. Myasthenia gravis patients; 5. Pregnant or breastfeeding patients; 6. Those with previous allergic reactions to similar drugs; 7. Participated in other clinical trials in the last 3 months; 8. Those with poor compliance and unable to strictly implement the plan; 9. Those who are expected to die within 48 hours.

Design outcomes

Primary

Measure	Time frame
Incidence of septic cardiomyopathy;	—

Countries

China

Contacts

Public ContactDeng Liehua

Affiliated Hospital of Guangdong Medical University

glinson@126.com+86 13809752886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026